[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 38 of about 38
1. Mössner J: What's new in therapy of pancreatic cancer? Dig Dis; 2010;28(4-5):679-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What's new in therapy of pancreatic cancer?
  • BACKGROUND: Pancreatic cancer remains a dismal disease with a median survival after diagnosis of about 6 months.
  • METHODS: Clinical trials with regard to treatment of pancreatic cancer, published as full manuscripts within the last 3 years and available via PubMed, were evaluated.
  • RESULTS: Several factors have positive influences on survival after pancreas resection: well-differentiated tumor grade, low tumor size, no duodenal or major vessel invasion, no perineural invasion, negative lymph node status, resection margin negativity (R0), high-volume centers, presence of human equilibrative nucleoside transporter 1 in patients treated with gemcitabine, low preoperative tumor marker CA 19-9, and low bilirubin level.
  • The following factors seem to have no influence on survival after pancreas resection: age, blood loss and transfusion requirements following resection, location of tumor, and type of resection.
  • Adjuvant chemotherapy after R0 resection is standard: gemcitabine seems to be superior to 5-FU or no therapy.
  • Nevertheless, only a few patients survive for at least 5 years after R0 resection and adjuvant chemotherapy.
  • Most patients need palliative treatment.
  • Besides best supportive care including nutritional support, therapy for pain and endoscopic treatment of jaundice, gemcitabine is standard in both locally advanced and metastatic disease.
  • None of the studied combinations of various therapies have demonstrated any additional benefits.
  • CONCLUSION: There are no real medical breakthroughs with regards to improving the prognosis of pancreatic cancer.
  • [MeSH-major] Pancreatic Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Palliative Care. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21088420.001).
  • [ISSN] 1421-9875
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


2. Ma J, Kimura W, Takeshita A, Hirai I, Moriya T, Mizutani M: Neuroendocrine carcinoma of the stomach with peripancreatic lymph node metastases successfully treated with pancreaticoduodenectomy. Hepatogastroenterology; 2007 Oct-Nov;54(79):1945-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An upper gastrointestinal endoscopy revealed a 4x4-cm fungating tumor with its fundus locating mainly in the duodenal bulbus and extending to the gastric antrum, and tumor biopsy revealed the histological findings of adenocarcinoma.
  • Computed tomography (CT) showed a large mass in the duodenal bulbus with regional lymph node metastases.
  • The patient's disease was diagnosed as primary duodenal cancer with regional lymph node metastases preoperatively.
  • During the operation, an obviously swollen lymph node on the anterior surface of the head of the pancreas 4.0 x 3.5 cm in size was found growing into the parenchyma of the pancreas head and could not be separated from the pancreas, and the swollen lymph node along the superior mesenteric vein was also hard and suspected to be a metastatic node.
  • The obvious swollen lymph node on the anterior surface of the head of the pancreas and the swollen lymph node along the superior mesenteric vein were also identified as metastatic lymph nodes.
  • Adjuvant chemotherapy with TS-1 was administered on an out-patient basis 6 weeks after the operation.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Duodenum / pathology. Endoscopy, Gastrointestinal. Humans. Immunohistochemistry. Lymph Node Excision. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Pancreaticoduodenectomy. Silicates / therapeutic use. Titanium / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TITANIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251134.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Silicates; 12067-57-1 / titanium silicide; D1JT611TNE / Titanium
  •  go-up   go-down


3. Van Cutsem E, Aerts R, Haustermans K, Topal B, Van Steenbergen W, Verslype C: Systemic treatment of pancreatic cancer. Eur J Gastroenterol Hepatol; 2004 Mar;16(3):265-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic treatment of pancreatic cancer.
  • Patients with pancreatic cancer have a poor prognosis although systemic treatment has slightly improved the outcome for those with advanced pancreatic cancer, The approach to a patient with pancreatic cancer remains a great challenge.
  • Patients often present with advanced disease and many are already in poor general condition at the time of diagnosis.
  • Today, surgery remains the only curative therapeutic option.
  • The reference treatment in patients with metastatic pancreatic cancer is gemcitabine.
  • The median survival of patients with advanced pancreatic cancer who are treated with gemcitabine is approximately 6 months and only approximately 20% of patients will be alive at 1 year.
  • Since most patients will relapse after complete surgical resection of pancreatic cancer, a search for a better adjuvant or neoadjuvant treatment is important.
  • Although several randomized studies have suggested an improved outcome for a postoperative chemoradiotherapy or chemotherapy, the role of an adjuvant treatment remains today controversial.
  • The systematic evaluation of new drugs in well designed clinical trials and the search for new molecular targets for treatment are crucial in our aim to improve the outcome for patients with pancreatic cancer.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cholestasis / surgery. Clinical Trials as Topic. Combined Modality Therapy / methods. Duodenal Obstruction / surgery. Humans. Neoplasm Recurrence, Local. Palliative Care / methods. Postoperative Care / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15195889.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 77
  •  go-up   go-down


Advertisement
4. Goldstein D, Tan BS, Rossleigh M, Haindl W, Walker B, Dixon J: Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study. Oncology; 2005;69(4):326-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
  • The aim of this analysis was to report on our experience of the utility of coincidence positron emission tomography (co-PET) based on an 18F-FDG gamma camera in assessing treatment response to imatinib using CT as the comparator and the final clinical outcome as the end point.
  • All patients had biopsy-proven malignant GIST and were on treatment with the targeted pharmacotherapeutic agent imatinib.
  • The majority of the patients were receiving treatment as part of the randomized trial of the European Organization for Research and Treatment of Cancer, the Australian Gastrointestinal Trials Group and the Italian Sarcoma Group, comparing 400 with 800 mg (400 mg b.i.d.).
  • There were 10 primary lesions (4 stomach, 4 duodenal, 2 small bowel), 9 of which were demonstrated on initial 18F-FDG co-PET examinations (90%).
  • There were 17 extrahepatic metastatic sites, 15 of which were visualized on the initial 18F-FDG study (88%).
  • CONCLUSION: 18F-FDG co-PET is a useful modality to monitor treatment response to imatinib in patients with malignant GIST.
  • Although there is a relatively reduced sensitivity when compared with CT for the detection of lesions especially in the liver, co-PET changes in several instances precede the changes on CT scanning.
  • This modality has the potential to influence clinical decision making and should be considered as part of the standard care of patients on imatinib.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Fluorodeoxyglucose F18. Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / pathology. Piperazines / therapeutic use. Positron-Emission Tomography. Pyrimidines / therapeutic use. Tomography, X-Ray Computed
  • [MeSH-minor] Benzamides. Gamma Cameras. Humans. Imatinib Mesylate. Radiopharmaceuticals. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16293972.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


5. Thompson JL, Blute ML: Coffee grounds emesis: rare presentation of testicular cancer treated with neoadjuvant chemotherapy. Urology; 2004 Aug;64(2):376-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coffee grounds emesis: rare presentation of testicular cancer treated with neoadjuvant chemotherapy.
  • Fewer than 5% of patients with metastatic testicular cancer present with gastrointestinal involvement.
  • We present the case of a previously healthy 26-year-old man who had symptomatic gastrointestinal bleeding caused by metastatic testicular cancer.
  • He was treated with orchiectomy, cisplatin-based neoadjuvant chemotherapy, and finally, resection of the residual retroperitoneal mass.
  • We believe that neoadjuvant chemotherapy, followed by surgical debulking, is the appropriate therapeutic sequence when treating an otherwise stable patient with metastatic testicular tumor involving the gastrointestinal tract.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Embryonal / secondary. Chemotherapy, Adjuvant. Duodenal Neoplasms / secondary. Hematemesis / etiology. Neoadjuvant Therapy. Orchiectomy. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Humans. Male

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15302504.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 3
  •  go-up   go-down


6. Milchgrub S, Wistuba II, Kim BK, Rutherford C, Urban J, Cruz PD Jr, Gazdar AF: Molecular identification of metastatic cancer to the skin using laser capture microdissection: a case report. Cancer; 2000 Feb 15;88(4):749-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular identification of metastatic cancer to the skin using laser capture microdissection: a case report.
  • BACKGROUND: In the current study the authors report a 57-year-old woman with a scalp tumor and cervical lymphadenopathy who had a previously resected duodenal carcinoid.
  • Histologic and immunophenotypic characteristics of the duodenal carcinoid differed from those of the scalp and cervical lymph node tumors, prompting the use of molecular methodologies to make the diagnosis.
  • METHODS: Paraffin embedded tissues from the duodenal carcinoid, scalp, and lymph node tumors were dissected using microscopic visualization and laser capture microdissection.
  • Microdissected lymphocytes from the three tissues were used as source of constitutional DNA (controls).
  • CONCLUSIONS: The shared molecular abnormalities among the three tumors indicated a common clonal origin, leading to a diagnosis of primary duodenal carcinoid with clear cell metastases to the scalp and cervical lymph nodes.
  • These findings led to radiation therapy and immunotherapy rather than chemotherapy.
  • This case illustrates the novel application of laser capture microdissection combined with PCR-based analyses of genomic markers for the identification of the origin of metastatic disease.
  • [MeSH-major] Carcinoid Tumor / diagnosis. Carcinoid Tumor / secondary. Duodenal Neoplasms / pathology. Genetic Markers. Skin Neoplasms / diagnosis. Skin Neoplasms / secondary


7. Katsinelos P, Kountouras J, Germanidis G, Paroutoglou G, Paikos D, Lazaraki G, Pilpilidis I, Chatzimavroudis G, Fasoulas K, Zavos C: Sequential or simultaneous placement of self-expandable metallic stents for palliation of malignant biliary and duodenal obstruction due to unresectable pancreatic head carcinoma. Surg Laparosc Endosc Percutan Tech; 2010 Dec;20(6):410-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential or simultaneous placement of self-expandable metallic stents for palliation of malignant biliary and duodenal obstruction due to unresectable pancreatic head carcinoma.
  • BACKGROUND: Pancreatic cancer is generally not amenable to curative resection, and self-expanding metallic stents have been used to relieve obstruction of bile duct and duodenum in patients with unresectable pancreatic cancer.
  • However, both relative experience with sequential or simultaneous endoscopic stents placement in biliary and duodenal stricture and long-term efficacy of these stents are limited.
  • The aim of this study was to present our experience on the effectiveness of this form of endoscopic treatment.
  • PATIENTS AND METHODS: We performed a retrospective review of all patients undergoing sequential or simultaneous biliary and duodenal stent placement for biliary and symptomatic duodenal obstruction due to unresectable pancreatic head carcinomas in 4 tertiary endoscopic centers.
  • RESULTS: Thirty-nine patients with unresectable pancreatic head cancer were included.
  • Biliary or duodenal stenting was unsuccessful in 7 patients (17.9%).
  • The remaining 32 patients (median age: 77 y; range: 52 to 82 y), with locally advanced (n=21) or metastatic disease (n=11), were studied.
  • Twenty-one patients (65.6%) received at least first-line chemotherapy.
  • Overall median survival was 9 months (range: 2 to 22 mo), being higher in locally advanced (median survival: 11.5 mo, range: 4 to 22 mo) than metastatic disease (median survival: 3 mo, range: 2 to 5.5 mo) (P<0.001).
  • Median duodenal and biliary patency was 3 months (range: 1 to 12 mo) and 9 months (range: 2 to 22 mo), respectively (P<0.05).
  • No major complications or death occurred in relation to endoscopic treatment.
  • CONCLUSIONS: Placement of self-expandable metal stents is a safe and efficacious palliation method for biliary and duodenal obstruction due to unresectable pancreatic head carcinoma.
  • [MeSH-major] Cholestasis, Extrahepatic / therapy. Duodenal Obstruction / therapy. Pancreatic Neoplasms / complications. Stents
  • [MeSH-minor] Aged. Aged, 80 and over. Catheterization. Cholangiopancreatography, Endoscopic Retrograde. Endoscopy, Digestive System. Female. Humans. Male. Middle Aged. Palliative Care. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21150420.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


8. Goldstein D, Carroll S, Apte M, Keogh G: Modern management of pancreatic carcinoma. Intern Med J; 2004 Aug;34(8):475-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic cancer remains a fearsome disease.
  • New insights into the molecular pathogenesis may influence choice of treatment modalities and provide avenues for novel therapeutic strategies for testing in the clinic.
  • The survival rate of patients with all stages of disease is poor and clinical trials are appropriate alternatives for treatment and should be considered.
  • Surgical resection, when possible, remains the primary treatment modality and can result in long-term cure.
  • The role of adjuvant therapy is re-emerging.
  • Patients with unresectable and metastatic disease are incurable and optimal palliation is the goal.
  • These patients may benefit from palliative bypass of biliary or duodenal obstruction if symptomatic.
  • Pain associated with local tumour infiltration may be palliated with radiation, with or without chemotherapy, or with coeliac nerve blocks or local neurosurgical procedures.
  • Chemotherapy with gemcitabine has modest objective response rates but has been shown to improve symptoms.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / therapy. Pancreatectomy / methods. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant / methods. Clinical Trials as Topic. Humans. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15317546.001).
  • [ISSN] 1444-0903
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 70
  •  go-up   go-down


9. Kulke MH: Metastatic pancreatic cancer. Curr Treat Options Oncol; 2002 Dec;3(6):449-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic pancreatic cancer.
  • Metastatic pancreatic cancer is one of the leading causes of cancer-related deaths in North America and Europe.
  • In the past, patients with metastatic pancreatic cancer have had few treatment options.
  • However, recently, several effective palliative therapies and procedures have become available.
  • The systemic administration of gemcitabine has been shown to result in clinical benefit and in a prolongation of median survival, and is now established as the standard first-line treatment for patients with metastatic pancreatic cancer.
  • Clinical trials are exploring whether the use of gemcitabine-based chemotherapy combinations will result in further benefit.
  • Several novel chemotherapeutic and biologic agents appear promising, and are likely to play a role in the treatment of patients with pancreatic cancer in the future.
  • Palliative procedures, such as biliary or duodenal stenting and celiac plexus blockade, should be considered in conjunction with systemic therapy in patients with specific complications from pancreatic cancer.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Palliative Care. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Autonomic Nerve Block. Celiac Plexus. Cholestasis / etiology. Cholestasis / therapy. Clinical Trials as Topic. Combined Modality Therapy. Digestive System Diseases / surgery. Fluorouracil / therapeutic use. Gastric Outlet Obstruction / etiology. Gastric Outlet Obstruction / therapy. Humans. Neoplasm Metastasis. Neuralgia / etiology. Neuralgia / therapy. Risk Factors. Stents


10. Perez EA, Gandara DR, Edelman MJ, O'Donnell R, Lauder IJ, DeGregorio M: Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies. Cancer Invest; 2003;21(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies.
  • Serum concentrations of tamoxifen and its hydroxylated metabolite N-desmethyltamoxifen were determined by high-performance liquid chromatography (HPLC) on day eight of the first treatment cycle in seven patients.
  • RESULTS: Fifteen patients with advanced malignancies received treatment with tamoxifen at 160 mg/m2, 200 mg/m2, and 250 mg/m2 per cycle, respectively.
  • The level of antitumor activity in nonsmall cell lung cancer NSCLC is encouraging (partial response in 4/10 patients).
  • Based on these data, a Phase II study of high-dose tamoxifen in combination with cisplatin in patients with metastatic NSCLC is being conducted through the Southwest Oncology Group.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Drug Administration Schedule. Duodenal Neoplasms / drug therapy. Female. Hematologic Diseases / chemically induced. Humans. Male. Middle Aged. Remission Induction. Tamoxifen / administration & dosage. Tamoxifen / adverse effects. Tamoxifen / pharmacokinetics. Thymoma / drug therapy. Thymus Neoplasms / drug therapy. Thyroid Neoplasms / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12643003.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Hirai S, Hamanaka Y, Mitsui N, Sato K, Chatani N: [Solitary metachnonous jejunum and duodenum metastasis after surgical resection of lung cancer]. Kyobu Geka; 2010 Feb;63(2):129-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solitary metachnonous jejunum and duodenum metastasis after surgical resection of lung cancer].
  • We report a rare case of a 58-year-old man of long-term survival after surgical treatment of solitary metachnonous jejunum and duodenum metastasis from lung cancer.
  • He underwent right upper lobectomy with a diagnosis of lung cancer which was histologically diagnosed as large cell carcinoma (pT4-MONO, stage IIIB).
  • Partial resection of the jejunum and postoperative chemotherapy were performed.
  • Two years after the 2nd surgery, another metastatic tumor was found in the duodenum, and pancreatoduodenectomy was performed.
  • The postoperative course of the patient was uneventful without recurrence 6 years after surgical resection of lung cancer.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / surgery. Duodenal Neoplasms / secondary. Jejunal Neoplasms / secondary. Lung Neoplasms / pathology. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20141081.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Laiyemo AO, Jack M, Dawkins FW, Smoot DT: Upper gastrointestinal bleeding from metastatic testicular cancer. J Natl Med Assoc; 2009 Aug;101(8):808-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper gastrointestinal bleeding from metastatic testicular cancer.
  • His medical history was significant for testicular cancer for which he had undergone orchiectomy, lymphadenectomy, and platinum-based chemotherapy.
  • Biopsy revealed mixed germ cell tumor with immature teratoma, the same histology as his testicular cancer.
  • His chemotherapy was changed to an ifosphamide-based regimen and a repeat upper endoscopic examination 5 months later revealed complete resolution of previously noted polypoid duodenal mass lesions.
  • This also demonstrates the effectiveness of ifosphamide as second-line therapy in the setting of resistance to platinum-based therapy.
  • [MeSH-major] Duodenal Neoplasms / secondary. Gastrointestinal Hemorrhage / etiology. Testicular Neoplasms / complications. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Endoscopy, Digestive System. Humans. Male


13. Maire F, Hammel P, Ponsot P, Aubert A, O'Toole D, Hentic O, Levy P, Ruszniewski P: Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas. Am J Gastroenterol; 2006 Apr;101(4):735-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas.
  • BACKGROUND: Life expectancy in patients with unresectable pancreatic cancer has improved by using new chemotherapeutic regimens.
  • AIM: To evaluate the incidence of biliary and duodenal stenoses as well as technical success and short- and long-term patency of endoscopically deployed stents in patients with unresectable pancreatic cancer.
  • PATIENTS AND METHODS: All consecutive patients with unresectable cancer of the pancreatic head seen between January 1999 and September 2003 in our center were retrospectively studied.
  • Patients with biliary and/or duodenal stenoses underwent endoscopic stent insertion as first intention therapy.
  • RESULTS: One hundred patients, median age 65 yr (32-85), with locally advanced (62%) or metastatic (38%) pancreatic cancer were studied.
  • Eighty-three percent received at least one line of chemotherapy.
  • Biliary and duodenal stenoses occurred in 81 and 25 patients, respectively.
  • Duodenal stenting was successful in 24 patients (96%); among them, 96% required a single stent (median duration of stent patency 6 months [0.5-15.7]).
  • In the 23 patients who developed both biliary and duodenal stenoses, combined stenting was successful in 91% of cases.
  • No major complication or death occurred related to endoscopic treatment.
  • CONCLUSION: Endoscopic palliative treatment of both biliary and duodenal stenoses is safe and effective in the long term, including in patients with combined obstructions.
  • [MeSH-major] Adenocarcinoma / complications. Biliary Tract. Cholestasis, Extrahepatic / therapy. Duodenal Obstruction / therapy. Duodenum. Palliative Care. Pancreatic Neoplasms / complications. Stents
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholangiopancreatography, Endoscopic Retrograde. Common Bile Duct Diseases / etiology. Common Bile Duct Diseases / therapy. Endoscopy. Female. Humans. Male. Middle Aged. Survival Rate


14. Taniguchi M, Ookubo K, Ootsuka M, Akitake H, Maekawa T, Yoshioka S, Hama N, Kashiwazaki M, Tsujie M, Konishi M, Ebisui C, Fujimoto T: [A case of successful control of recurrent duodenal carcinoma receiving paclitaxel]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2315-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of successful control of recurrent duodenal carcinoma receiving paclitaxel].
  • We have experienced a case of successful control of recurrent duodenal carcinoma receiving paclitaxel chemotherapy.
  • Distal gastrectomy with D2 dissection was performed.
  • And 13a, 13b, 12a, p lymph nodes were dissected for duodenal carcinoma.
  • Recurrence of the duodenal carcinoma was diagnosed in February 2007, and S-1 administration was begun.
  • But, we dosed down with S-1 due to severe diarrhea.
  • In spite of combined S-1 and CPT-11 chemotherapy, the CEA level increased, and lymph nodes were getting larger.
  • She then underwent the paclitaxel chemotherapy during the 5 months without severe side effects.
  • The CEA level decreased significantly and metastatic lymph nodes were reduced observed by CT scan.
  • Paclitaxel chemotherapy is effective for duodenal cancer.
  • [MeSH-major] Duodenal Neoplasms / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Carnitine O-Palmitoyltransferase / therapeutic use. Drug Combinations. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Oxonic Acid / therapeutic use. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037407.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; EC 2.3.1.21 / Carnitine O-Palmitoyltransferase; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


15. Gravalos C, García-Sanchez L, Hernandez M, Holgado E, Alvarez N, García-Escobar I, Martínez J, Robles L: Surgical resection of a solitary pancreatic metastasis from colorectal cancer: a new step to a cure? Clin Colorectal Cancer; 2008 Nov;7(6):398-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection of a solitary pancreatic metastasis from colorectal cancer: a new step to a cure?
  • Isolated metastases to the pancreas from colorectal cancer (CRC) are very rare.
  • We report a case of a 37-year-old man with a hereditary nonpolyposis CRC with a solitary metastasis to the pancreas who was treated with right hemicolectomy, neoadjuvant chemotherapy, complete surgical resection of the pancreatic metastasis, and adjuvant chemotherapy.
  • Symptoms and signs might be similar in these diseases: pain, weight loss, obstructive jaundice, and duodenal obstruction.
  • Imaging techniques such as computed tomography, ultrasonography, magnetic resonance imaging, positron emission tomography, or endoscopic retrograde colangiopancreatography can provide relevant information about pancreatic lesions.
  • However, it remains difficult to distinguish primary from metastatic pancreatic tumors.
  • Additional chemotherapy is recommended.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Germ-Line Mutation. Humans. Male. MutS Homolog 2 Protein / genetics. Pedigree


16. Yabe N, Murai S, Akatsu T, Shoji T, Shimizu H, Fukushima H, Mitsugi Y, Ishida T, Amemiya T, Hasegawa H, Kitagawa Y: [A case of advanced gastric cancer resistant to S-1 successfully treated with weekly administration of paclitaxel]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2439-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer resistant to S-1 successfully treated with weekly administration of paclitaxel].
  • A 62-year-old female was diagnosed with type 2 advanced gastric cancer in May 2003.
  • Computed tomography (CT) revealed paraaortic lymph node metastasis, duodenal metastasis and ascites due to peritoneal dissemination.
  • Chemotherapy with CDDP+S-1 was started and continued.
  • After the chemotherapy, there were progressive diseases.
  • Clinical symptoms were relieved, and CT scan revealed metastatic lymph nodes were reduced after 4 cycles.
  • She was resected for a right temporal-occipital brain metastatic tumor, and local cerebral irradiation was performed.
  • After this operation, she was diagnosed with brain metastasis from advanced gastric cancer.
  • The procedure was interrupted for about 6 months.
  • After rehabilitation, PTX treatment was restarted as 14th cycle.
  • A weekly administration of PTX may be a promising regimen as second-line chemotherapy for S-1 resistant recurrent gastric cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents, Phytogenic / administration & dosage. Carcinoma / drug therapy. Oxonic Acid / therapeutic use. Paclitaxel / administration & dosage. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Brain Neoplasms / secondary. Drug Administration Schedule. Drug Combinations. Drug Resistance, Neoplasm. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224599.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


17. Gibson MK, Holcroft CA, Kvols LK, Haller D: Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist; 2005 Feb;10(2):132-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.
  • Response rates to palliative combination chemotherapy are low, and the median duration of survival for metastatic disease is less than 1 year.
  • This study aimed to document the response rate and survival time for patients with advanced small bowel adenocarcinoma who were not surgically curable and were treated with a regimen of 5-fluorouracil (5-FU), mitomycin C (Mutamycin; Bristol-Myers Squibb; Princeton, NJ), and doxorubicin (Adriamycin; Bedford Laboratories; Bedford, OH), the FAM regimen.
  • Chemotherapy was given as follows: 5-FU, 600 mg/m(2) on days 1, 8, 29 and 36; mitomycin C, 10 mg/m(2) on day 1; and doxorubicin, 30 mg/m(2) on days 1 and 29.
  • Prior chemotherapy was allowed.
  • Survival time and time to progression were evaluated by the method of Kaplan and Meier, and these outcomes were stratified by clinical and laboratory covariates.
  • The median survival time was 8 months.
  • CONCLUSIONS: The FAM regimen was active and tolerable for patients with advanced small bowel adenocarcinoma; however, the results were no better than those seen with other chemotherapy combinations.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Duodenal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Mitomycin / adverse effects. Neoplasm Metastasis / drug therapy. Neoplasm Recurrence, Local. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709215.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Sakamoto K, Tashiro Y, Niwa K, Ono S, Ishiyama S, Sugimoto K, Kamiyama H, Komiyama H, Takahashi M, Kojima Y, Tomiki Y, Ichikawa J: [A case of duodenal perforation during mFOLFOX6 treatment for metastatic sigmoid colon cancer]. Gan To Kagaku Ryoho; 2010 Dec;37(13):2925-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of duodenal perforation during mFOLFOX6 treatment for metastatic sigmoid colon cancer].
  • We present a case of metastatic sigmoid colon cancer causing duodenal perforation during modified FOLFOX6 chemotherapy.
  • The patient was a 68-year-old man who underwent sigmoidectomy for an advanced sigmoid cancer in September 2007.
  • He has been received mFOLFOX6 chemotherapy for multiple liver metastases since January 2009.
  • In March 2010, the patient complained of abdominal pain during the 24th course of chemotherapy, and was admitted to our hospital.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Duodenal Diseases / etiology. Intestinal Perforation / etiology. Sigmoid Neoplasms / complications. Sigmoid Neoplasms / drug therapy
  • [MeSH-minor] Aged. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Male. Organoplatinum Compounds / therapeutic use

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160272.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


19. Atalay C, Irkkan C, Pak I, Altinok M: Gastroduodenal metastases in a clear cell sarcoma patient. J Exp Clin Cancer Res; 2003 Mar;22(1):147-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other more common metastatic sites are bones, lymph nodes, liver and spleen.
  • Treatment of clear cell sarcoma is primarily surgical aiming to achieve uninvolved margins.
  • Role of chemotherapy, radiotherapy and immunotherapy is controversial and remission of metastases has been reported rarely.
  • In this study we report a case of clear cell sarcoma, with gastroduodenal and pulmonary metastases and remission of these metastases in response to chemotherapy.
  • [MeSH-major] Duodenal Neoplasms / secondary. Sarcoma, Clear Cell / pathology. Sarcoma, Clear Cell / secondary. Stomach Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Biopsy, Fine-Needle. Cisplatin / administration & dosage. Dacarbazine / administration & dosage. Humans. Male. Middle Aged. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12725335.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Oshima S, Makari Y, Iijima S, Kato T, Miyake Y, Hoshi M, Doi T, Miyo M, Sakamoto T, Kato A, Kurokawa E, Kikkawa N: [A successful case with CPT-11 + CDDP chemotherapy for recurrent gastric cancer of the remnant stomach]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2455-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A successful case with CPT-11 + CDDP chemotherapy for recurrent gastric cancer of the remnant stomach].
  • We report a successful case with irinotecan (CPT-11 60 mg/m2) + cisplatin (CDDP 30 mg/m2) chemotherapy (once in 2 weeks) for recurrent gastric cancer of the remnant stomach.
  • A 77-year-old man was performed a distal gastrectomy for duodenal ulcer 42 years ago.
  • He had a total gastrectomy for gastric cancer of remnant stomach when he was at 73 years old.
  • After the surgery, we treated this patient with S-1 mono-therapy for five courses.
  • However, we finished this treatment for lymph-node metastases.
  • We finished this treatment after 12 courses for anemia (grade 3).
  • After the treatment, the metastatic lymph-nodes appeared in no change.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastric Stump. Neoplasm Recurrence, Local / drug therapy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224604.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


21. Chan WH, Cheow PC, Chung AY, Ong HS, Koong HN, Wong WK: Pancreaticoduodenectomy for locally advanced stomach cancer: preliminary results. ANZ J Surg; 2008 Sep;78(9):767-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreaticoduodenectomy for locally advanced stomach cancer: preliminary results.
  • BACKGROUND: Pancreaticoduodenectomy (PD) for locally advanced stomach cancer involving duodenum or/and pancreatic head was controversial and rarely carried out.
  • METHODS: A review of prospective database from January 2003 to December 2006 of patients who had locally advanced stomach cancer involving duodenum or/and head of pancreas that precluded curative subtotal gastrectomy who underwent diagnostic laparoscopy or exploratory laparotomy to exclude peritoneal metastatic disease.
  • Patients were advised to undergo neoadjuvant chemotherapy before PD.
  • Only four patients had neoadjuvant chemotherapy before PD.
  • The median operative time was 8 h (range 6-9 h).
  • Three patients developed controlled pancreatic leaks and fistulas that were successfully treated with conservative measures.
  • Patients who received neoadjuvant chemotherapy seemed to have better survival rate (P = 0.039).
  • CONCLUSION: Our initial experience has shown that with careful and stringent patients selection, PD for locally advanced stomach cancer can be carried out with acceptable morbidity and mortality.
  • Early results for patients who received neoadjuvant chemotherapy showed trend towards prolonged survival.
  • [MeSH-major] Duodenal Neoplasms / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy. Stomach Neoplasms / surgery
  • [MeSH-minor] Feasibility Studies. Humans. Neoplasm Invasiveness. Treatment Outcome


22. Oosting SF, Peters FT, Hospers GA, Mulder NH: A patient with metastatic melanoma presenting with gastrointestinal perforation after dacarbazine infusion: a case report. J Med Case Rep; 2010;4:10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with metastatic melanoma presenting with gastrointestinal perforation after dacarbazine infusion: a case report.
  • INTRODUCTION: We report a rare case of gastrointestinal perforation following dacarbazine infusion for metastatic melanoma.
  • A computed tomography scan showed massive ascites, lymphadenopathy and liver lesions suspect for metastases.
  • Histological examination of a duodenal lesion was consistent with a diagnosis of metastatic melanoma.
  • The patient was started on systemic treatment with dacarbazine 800 mg/m2 every three weeks and he was discharged one day after the first dose.
  • A laparotomy was discussed with the patient and his family but he decided to go home with symptomatic treatment.
  • Gastrointestinal perforations due to responding tumors are a well-known complication of systemic treatment of gastrointestinal lymphomas.
  • However, as the response rate of metastatic melanoma to dacarbazine is only 10% to 20%, and responses are usually only partial, perforation due to treatment response in metastatic melanoma is rare.Medical oncologists should be aware of the risk of bowel perforation after starting cytotoxic chemotherapy on patients with gastrointestinal metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1978 Jun;135(6):807-10 [665907.001]
  • [Cites] Cancer. 1988 May 15;61(10):2134-5 [3359409.001]
  • [Cites] J Pediatr Surg. 1999 Jul;34(7):1169-74 [10442615.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2105-16 [10561265.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2745-51 [10561349.001]
  • [Cites] Cancer Treat Rev. 2008 Apr;34(2):145-56 [18077098.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(2):CD001215 [10796759.001]
  • [Cites] Arch Surg. 1964 Jun;88:969-73 [14132002.001]
  • [Cites] Mayo Clin Proc. 2006 Apr;81(4):511-6 [16610571.001]
  • [Cites] J Pediatr Surg. 2007 Mar;42(3):E1-3 [17336175.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):158-66 [10623706.001]
  • (PMID = 20180962.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2829594
  •  go-up   go-down


23. Ichinose Y, Yosimori K, Yoneda S, Kuba M, Kudoh S, Niitani H: UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma: a multiinstitutional phase II trial. For the Japan UFT Lung Cancer Study Group. Cancer; 2000 Jan 15;88(2):318-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma: a multiinstitutional phase II trial. For the Japan UFT Lung Cancer Study Group.
  • BACKGROUND: Combination chemotherapy comprised of oral UFT (a combination of tegafur and uracil) and cisplatin was shown to be an effective regimen for the treatment of advanced nonsmall cell lung carcinoma and to be associated with a low incidence rate of toxicity in a previous, single institution, Phase II trial on a small patient sample.
  • Patients who had received prior treatment were excluded.
  • Treatment was repeated every 3-4 weeks.
  • RESULTS: Approximately 70% of the 108 eligible patients had systemic metastatic disease.
  • The median survival time was 40 weeks and the 1-year survival rate was 39% (95% CL, 30-49%).
  • The median progression free survival time was 28 weeks.
  • One patient who had a past history of duodenal ulcer died of ulcer perforation 15 days after completing the first treatment cycle.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Injections, Intravenous. Male. Middle Aged. Survival Analysis. Tegafur / administration & dosage. Treatment Outcome. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10640963.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q20Q21Q62J / Cisplatin; FP protocol
  •  go-up   go-down


24. Fazio N, Orsi F, Grasso RF, Ferretti G, Medici M, Rocca A, Zampino G, Curigliano G, De Pas T, Colleoni M, Bonomo G, Marrocco E, Lunghi L, De Braud F: Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinoma. Anticancer Res; 2003 Nov-Dec;23(6D):5023-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinoma.
  • BACKGROUND: Hepatic intra-arterial chemotherapy (HIAC) leads to a higher response rate than systemic administration in untreated patients with liver metastases from colorectal cancer (CRC).
  • PATIENTS AND METHODS: Forty-five CRC patients with liver-only or liver-dominant metastases, resistant or refractory to previous systemic therapy, were treated using a temporary trans-subclavian catheter.
  • A 3-day chemotherapy regimen of daily 5-fluorouracil (5-FU) 1000 mg/m2/day + heparin 5000 IU/day given as a 24-hour continuous infusion, and twice daily bolus injections of cisplatin (CDDP) 10 mg/m2 and mitomycin C (MMC) 2 mg/m2, was administered every six weeks.
  • Eleven of the 16 responding patients had been refractory to a previous 5-FU-based systemic therapy.
  • Gastro-duodenal ulcers occurred in nine patients.
  • CONCLUSION: HIAC with 5-FU, CDDP and MMC given through a temporary percutaneous catheter is safe and active in pretreated patients with metastatic CRC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colorectal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. HEPARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14981962.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 9005-49-6 / Heparin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


25. Gallagher DJ, Capanu M, Raggio G, Kemeny N: Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. Ann Oncol; 2007 Dec;18(12):1995-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis.
  • BACKGROUND: Response rates to systemic chemotherapy are low after tumor progression on oxaliplatin regimens.
  • Hepatic arterial infusion (HAI) therapy in patients with tumor progression is a viable alternative.
  • Median time to hepatic progression was 8.6 months, and median time to overall progression was 6.5 months.
  • Median survival from time of initiation of HAI was 20.1 months [95% confidence interval (CI) 16.9-21.4] and from the initiation of treatment of metastatic disease, 32.01 months (95% CI 29.1-34.6).
  • Grade 3/4 toxic effects included neutropenia (13%), diarrhea (15%), intra-abdominal hemorrhage (2%), and bleeding duodenal ulcer (2%).

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962209.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


26. Wang HY, Chen MJ, Yang TL, Chang MC, Chan YJ: Carcinoid tumor of the duodenum and accessory papilla associated with polycythemia vera. World J Gastroenterol; 2005 Jun 28;11(24):3794-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinoid tumors have been reported in a wide range of organs but most frequently involve the gastrointestinal tract; however, duodenal carcinoid tumors are rare.
  • He received periodic phlebotomy and hydroxyurea treatment.
  • The possible origin of UGI bleeding by a duodenal carcinoid tumor, although rare, should be considered.
  • There has been one case report of a duodenal carcinoid tumor that involved accessory papilla of the pancreas divisum and one case report of metastatic carcinoid tumor associated with polycythemia vera.
  • It is different in our patient as compared with the latter report, which mentioned a polycythemia vera patient who was found to have a metastatic carcinoid in the 17 years follow-up period.
  • Chemotherapy had been given before the carcinoid tumor was revealed.
  • Our patient had no previous chemotherapy for polycythemia vera before he was found to have duodenal carcinoid tumor; this excludes the possibility of chemotherapy induced carcinoid tumor, although it had been suspected in the previous report.
  • [MeSH-major] Carcinoid Tumor / complications. Duodenal Neoplasms / complications. Pancreatic Ducts / pathology. Polycythemia Vera / complications


27. Ohno T, Koguchi H, Miura A, Tanaka Y, Endo M, Matsunaga S, Hasegawa I, Kato A, Tokuda Y, Sakakibara K: [A case of advanced ampullary carcinoma successfully resected after primary chemotherapy with s-1 and gemcitabine]. Gan To Kagaku Ryoho; 2009 Jun;36(6):999-1002
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced ampullary carcinoma successfully resected after primary chemotherapy with s-1 and gemcitabine].
  • Immediately after relief from obstructive jaundice, combination chemotherapy of S-1 and gemcitabine was given.
  • Subsequently, CA19-9, the tumormarker level was reduced, the metastatic liver tumor disappeared, and the size of the primary lesion was remarkably reduced.
  • This is a very instructive case for developing effective chemotherapy options to treat biliary tract cancers involving ampullary carcinoma.
  • [MeSH-major] Ampulla of Vater. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Duodenal Neoplasms / drug therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Combinations. Humans. Jaundice, Obstructive / etiology. Male. Middle Aged. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542724.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


28. Gil HW, Won JH, Lee NS, Lee SC, Kim SE, Kim CK, Lee KT, Park SK, Baick SH, Hong DS, Park HS: Metastasis to the Thigh Skeletal Muscle from an Adenocarcinoma of the Duodenum. Cancer Res Treat; 2002 Oct;34(5):394-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Skeletal muscle is one of the most unusual metastatic sites for any malignancy.
  • Duodenal cancer is extremely rare, and no cases of skeletal muscle metastasis from duodenal cancer have been reported.
  • We report here in a case of metastasis to the skeletal muscle of the left thigh from duodenal cancer.
  • An imaging study, and a biopsy, revealed a duodenal adenocarcinoma metastasize to the skeletal muscle.
  • The patient refused chemotherapy and has followed up for 4 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 26680893.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Keywords] NOTNLM ; Duodenal neoplasm / Metastasis / Skeletal muscle
  •  go-up   go-down


29. Satomi D, Morishima Y, Suzuki I, Aoki Y, Tazawa Y, Kobayashi J, Toyoda Y, Yoshida Y, Yamamoto K, Mori M, Nakano M: [A case of successful control for primary duodenal cancer with combined CPT-11, CDDP and DOC chemotherapy]. Gan To Kagaku Ryoho; 2008 Oct;35(10):1753-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of successful control for primary duodenal cancer with combined CPT-11, CDDP and DOC chemotherapy].
  • We have experienced a rare case of primary duodenal carcinoma with perforation of the duodenum.
  • Combined CPT- 11, CDDP and DOC chemotherapy achieved a partial response.
  • Endoscopic examination and biopsy after surgery showed duodenal adenocarcinoma.
  • Therefore, we diagnosed primary duodenal carcinoma with metastasis to the periaortic lymph nodes.
  • Combined CPT-11, CDDP and DOC chemotherapy were performed.
  • Metastatic lymph nodes were reduced from CT scan after three courses, and successfully controlled until nine courses.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Cisplatin / therapeutic use. Duodenal Neoplasms / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Duodenoscopy. Humans. Male. Middle Aged. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18931582.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


30. Fujiwara Y, Naomoto Y, Tanabe S, Sakurama K, Noma K, Nishikawa T, Motoki T, Takaoka M, Shirakawa Y, Yamatsuji T, Matsuoka J, Tanaka N: [A case report of FOLFOX treatment for primary duodenal carcinoma with multiple liver metastases]. Gan To Kagaku Ryoho; 2009 Apr;36(4):655-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of FOLFOX treatment for primary duodenal carcinoma with multiple liver metastases].
  • We report a case of a woman in her sixties having primary duodenal carcinoma with multiple liver metastases who was treated with oxaliplatin in combination with infusional 5-fluorouracil/Leucovorin(FOLFOX regimen).
  • After completing 2 courses of the chemotherapy, computed tomography showed a partial response without any severe adverse events.
  • So far, no standard therapeutic strategy for metastatic duodenal carcinoma has been developed.
  • However, we suggest a FOLFOX regimen can be highly effective as a safe approach for continuously maintaining the quality of life of patients with this rare type of cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Duodenal Neoplasms / drug therapy. Duodenal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Biomarkers, Tumor / blood. Duodenoscopy. Female. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Organoplatinum Compounds / therapeutic use. Positron-Emission Tomography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19381042.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


31. Kikuchi T, Asano N, Noguchi T, Nomura E, Uchimi K, Kagaya H, Suzuki S, Suzuki M, Kayaba Y, Tateno H, Onodera H: [A case of primary gastric mantle cell lymphoma]. Nihon Shokakibyo Gakkai Zasshi; 2009 Aug;106(8):1168-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After 6 months, erosions also formed in the duodenal bulb and systemic lymph nodes become enlarged.
  • After 20 months, the gastroduodenal erosions developed into mucosal ulcers, and the systemic lymph node swelling progressed.
  • The gastroduodenal lesions and atypical cells in the bone marrow disappeared after 2 cycles of the chemotherapy.
  • Metastatic lymph node swelling regressed after stem cell transplantation.
  • [MeSH-minor] Combined Modality Therapy. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged


32. Imamura M: Recent standardization of treatment strategy for pancreatic neuroendocrine tumors. World J Gastroenterol; 2010 Sep 28;16(36):4519-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent standardization of treatment strategy for pancreatic neuroendocrine tumors.
  • For curative resection of functioning PNET associated with multiple endocrine neoplasia type 1 (MEN 1) which are usually multiple and sometimes numerous, resection surgery of the pancreas and/or the duodenum has to be performed based on localization by the SASI test.
  • For example, in patients with Zollinger-Ellison syndrome (ZES), duodenal gastrinoma has been detected more frequently than pancreatic gastrinoma, and in patients with MEN 1 and ZES, gastrinomas have been located mostly in the duodenum, and pancreatic gastrinoma has been found to co-exist in 13% of patients.
  • Nonfunctioning PNET in patients with MEN 1 becomes metastatic to the liver when it is more than 1 cm in diameter and should be resected after careful observation.
  • The treatment strategy for hepatic metastases of PNET has not been established and aggressive resection with chemotherapy and trans-arterial chemoembolization have been performed with significant benefit.
  • The usefulness of octreotide treatment and other molecular targeting agents are currently being assessed.
  • [MeSH-major] Neuroendocrine Tumors / therapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Animals. Diagnosis, Differential. Gastrins / blood. Humans. Liver Neoplasms / secondary. Male. Multiple Endocrine Neoplasia Type 1 / pathology. Multiple Endocrine Neoplasia Type 1 / surgery. Secretin. Zollinger-Ellison Syndrome / pathology. Zollinger-Ellison Syndrome / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1992 Feb;87(2):195-200 [1734697.001]
  • [Cites] J Gastroenterol. 2010 Feb;45(2):234-43 [20058030.001]
  • [Cites] J Am Coll Surg. 2000 Apr;190(4):432-45 [10757381.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1425-30 [11038217.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5282-93 [11701693.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Dec;57(6):821-5 [12460333.001]
  • [Cites] Radiology. 2003 Feb;226(2):441-51 [12563138.001]
  • [Cites] Ann Surg. 2004 May;239(5):637-45; discussion 645-7 [15082967.001]
  • [Cites] Gastroenterology. 1972 Apr;62(4):626-31 [5020875.001]
  • [Cites] Ann Surg. 1987 Mar;205(3):230-9 [3548610.001]
  • [Cites] Arch Surg. 1988 Jul;123(7):843-8 [2838008.001]
  • [Cites] Ann Surg. 1989 Dec;210(6):710-8 [2589884.001]
  • [Cites] Pancreas. 1990 Jul;5(4):467-73 [2166285.001]
  • [Cites] Radiology. 1991 Jan;178(1):237-41 [1984311.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jan;74(1):204-10 [1727822.001]
  • [Cites] World J Surg. 1992 Jul-Aug;16(4):703-9; discussion 709-10 [1357832.001]
  • [Cites] World J Surg. 1993 Jul-Aug;17(4):481-8 [8103250.001]
  • [Cites] Ann N Y Acad Sci. 1994 Sep 15;733:416-24 [7978890.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):488-93; discussion 493-4 [7725733.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):88-92; discussion 92-3 [9660030.001]
  • [Cites] J Intern Med. 1998 Jun;243(6):495-500 [9681848.001]
  • [Cites] Ann Surg. 1998 Aug;228(2):228-38 [9712569.001]
  • [Cites] Ann Thorac Surg. 1999 Feb;67(2):532-3 [10197684.001]
  • [Cites] Acta Oncol. 2004;43(7):617-25 [15545182.001]
  • [Cites] World J Surg. 2005 Feb;29(2):203-7 [15650799.001]
  • [Cites] Neuroendocrinology. 2004;80(6):394-424 [15838182.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):757-64, discussion 764-6 [16327485.001]
  • [Cites] World J Surg. 2006 Jan;30(1):1-11 [16369713.001]
  • [Cites] Ann Surg. 2006 Sep;244(3):410-9 [16926567.001]
  • [Cites] Medicine (Baltimore). 2006 Nov;85(6):295-330 [17108778.001]
  • [Cites] Medicine (Baltimore). 2006 Nov;85(6):331-64 [17108779.001]
  • [Cites] Neuroendocrinology. 2006;83(5-6):380-6 [17016032.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):15-31 [17382263.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2986-91 [17505000.001]
  • [Cites] J Gastroenterol. 2007 Jun;42(6):497-500 [17671766.001]
  • [Cites] Endocr Pathol. 2007 Summer;18(2):79-85 [17916997.001]
  • [Cites] Endocr Pathol. 2007 Fall;18(3):150-5 [18058264.001]
  • [Cites] Neuroendocrinology. 2008;87(1):47-62 [18097131.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):61-72 [18177818.001]
  • [Cites] Ann Oncol. 2008 May;19(5):903-8 [18209014.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3063-72 [18565894.001]
  • [Cites] J Clin Oncol. 2008 Sep 10;26(26):4311-8 [18779618.001]
  • [Cites] Cancer. 2008 Oct 1;113(7 Suppl):1807-43 [18798544.001]
  • [Cites] J Exp Clin Cancer Res. 2009;28:15 [19208248.001]
  • [Cites] J Clin Oncol. 2010 Jan 1;28(1):69-76 [19933912.001]
  • [Cites] World J Surg. 2010 Feb;34(2):249-55 [19949948.001]
  • [Cites] Cancer J Sci Am. 1999 Nov-Dec;5(6):356-61 [10606477.001]
  • (PMID = 20857521.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Gastrins; 1393-25-5 / Secretin
  • [Other-IDs] NLM/ PMC2945482
  •  go-up   go-down


33. Auernhammer CJ, Göke B: Medical treatment of gastrinomas. Wien Klin Wochenschr; 2007;119(19-20):609-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical treatment of gastrinomas.
  • Surgery is first line treatment in gastrinomas, however often fails to be curative.
  • This manuscript reviews current strategies of medical treatment of surgically non-curable gastrinoma.
  • Symptomatic treatment with H(+)-K(+)-ATPase proton-pump inhibitors suppresses hypersecretion of gastric acid and substantially improves quality of life in patients with Zollinger-Ellison syndrome.
  • Further medical therapy is only recommended in cases of progressive metastatic gastrinoma.
  • In well differentiated neuroendocrine carcinoma (G1 and G2) a so-called biotherapy with somatostatin analogues exists as first-line and chemotherapy with streptocotozin plus doxorubicine/5-FU as second-line medical treatment option.
  • In poorly differentiated neuroendocrine carcinoma (G3) chemotherapy with etoposide plus cisplatin is possible.
  • Prospective future therapeutic strategies may include treatment with novel somatostatin analogues as well as angiogenesis inhibitors and kinase inhibitors targeting tumor-specific signaling cascades.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Duodenal Neoplasms / drug therapy. Gastrinoma / drug therapy. Gastrins / blood. Pancreatic Neoplasms / drug therapy. Proton Pump Inhibitors / therapeutic use. Somatostatin / analogs & derivatives. Zollinger-Ellison Syndrome / drug therapy
  • [MeSH-minor] Angiogenesis Inhibitors / therapeutic use. Clinical Trials as Topic. Humans. Interferon-alpha / therapeutic use. Octreotide / therapeutic use. Peptides, Cyclic / therapeutic use

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroendocrinology. 2004;80(6):394-424 [15838182.001]
  • [Cites] Virchows Arch. 2006 Oct;449(4):395-401 [16967267.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):234-40 [17200360.001]
  • [Cites] Endocr Rev. 2004 Jun;25(3):458-511 [15180952.001]
  • [Cites] Cancer Res. 2007 May 15;67(10 ):5025-32 [17510435.001]
  • [Cites] Ann Oncol. 2007 Aug;18(8):1307-13 [17301070.001]
  • [Cites] Ann Chir. 2004 Apr;129(3):149-55 [15142812.001]
  • [Cites] Can J Gastroenterol. 2001 Dec;15(12):795-8 [11773945.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):649-56 [16183533.001]
  • [Cites] Neuroendocrinology. 2004;80 Suppl 1:8-11 [15477708.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Aug;3(8):761-71 [16234004.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71 [11739416.001]
  • [Cites] Drugs. 2005;65 Suppl 1:13-23 [16335854.001]
  • [Cites] Drugs. 2001;61(15):2327-56 [11772142.001]
  • [Cites] Drugs. 2005;65 Suppl 1:113-26 [16335865.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14 ):2689-96 [12860945.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3233-42 [15867218.001]
  • [Cites] Gastroenterology. 1993 Oct;105(4):1179-83 [8405864.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2292-309 [16258976.001]
  • [Cites] Gastroenterology. 1992 Mar;102(3):767-78 [1537514.001]
  • [Cites] Digestion. 2005;71(3):131-40 [15785039.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2154-9 [10570446.001]
  • [Cites] Neuroendocrinology. 2006;84(1):42-8 [17047316.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):331-43 [11900219.001]
  • [Cites] J Neuroendocrinol. 2006 May;18(5):355-60 [16629834.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):209-10 [16014895.001]
  • [Cites] Cancer. 2007 Apr 15;109(8):1478-86 [17340592.001]
  • [Cites] Neuroendocrinology. 2006;84(3):212-5 [17312381.001]
  • [Cites] Acta Oncol. 2004;43(7):626-36 [15545183.001]
  • [Cites] Gut. 2005 Jun;54 Suppl 4:iv1-16 [15888809.001]
  • [Cites] Lancet. 1986 Dec 6;2(8519):1307-9 [2878177.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):554-62 [16397272.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1329-35 [15920550.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):675-97 [16253893.001]
  • [Cites] Am J Gastroenterol. 1999 May;94(5):1381-7 [10235222.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1101-7 [11571721.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1148-54 [17031397.001]
  • [Cites] Gastroenterol Clin Biol. 1991;15(5):393-8 [1830020.001]
  • [Cites] Metabolism. 1990 Sep;39(9 Suppl 2):156-62 [2402220.001]
  • [Cites] Neuroendocrinology. 2007;85(1):45-53 [17341847.001]
  • [Cites] Am J Med. 1998 May;104(5):422-30 [9626024.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1717-51 [15887161.001]
  • [Cites] Endocrinology. 1994 Jan;134(1):301-6 [7903931.001]
  • [Cites] Surgery. 1988 Nov;104(5):834-42 [2903562.001]
  • [Cites] Arch Surg. 1992 Sep;127(9):1019-24; discussion 1024-6 [1514904.001]
  • [Cites] Lancet. 1986 Mar 8;1(8480):554-5 [2869278.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):615-30 [10080607.001]
  • [Cites] J Endocrinol Invest. 1999 Feb;22(2):144-6 [10195383.001]
  • [Cites] Gut. 2002 Jan;50(1):52-60 [11772967.001]
  • [Cites] Digestion. 2000;62 Suppl 1:73-8 [10940691.001]
  • [Cites] Neuroendocrinology. 2007;85(1):54-60 [17310129.001]
  • [Cites] Tumori. 2006 Nov-Dec;92(6):531-5 [17260495.001]
  • [Cites] Pancreas. 1988;3(2):145-52 [2897687.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1668-84 [15887158.001]
  • [Cites] Dig Dis Sci. 1993 Feb;38(2):245-56 [8425437.001]
  • [Cites] Neuroendocrinology. 2004;80 Suppl 1:23-7 [15477712.001]
  • [Cites] J Clin Gastroenterol. 1989 Jun;11(3):282-6 [2754214.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):227-32 [1712661.001]
  • [Cites] Aliment Pharmacol Ther. 1996 Aug;10(4):507-22 [8853754.001]
  • [Cites] Expert Opin Investig Drugs. 2007 Feb;16(2):219-24 [17243941.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):966-73 [15151956.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):68-85 [12105835.001]
  • [Cites] Br J Cancer. 1999 Dec;81(8):1351-5 [10604732.001]
  • [Cites] J Clin Oncol. 1999 Apr;17 (4):1111 [10561168.001]
  • [Cites] Acta Oncol. 2004;43(7):617-25 [15545182.001]
  • [Cites] Gastroenterology. 1988 Jun;94(6):1326-34 [2966088.001]
  • [Cites] Am J Clin Oncol. 2000 Aug;23 (4):412-5 [10955874.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1766-75 [14583782.001]
  • [Cites] Neuroendocrinology. 2006;84(3):173-82 [17312377.001]
  • [Cites] Neuroendocrinology. 2004;80 Suppl 1:94-8 [15477725.001]
  • [Cites] Endocr Rev. 2003 Oct;24(5):600-32 [14570746.001]
  • [Cites] Dig Dis Sci. 1991 Apr;36(4):394-404 [2007355.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Apr;62(4):434-43 [15807874.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4573-81 [10969809.001]
  • [Cites] Neuroendocrinology. 2004;80 Suppl 1:79-84 [15477723.001]
  • (PMID = 17985097.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Gastrins; 0 / Interferon-alpha; 0 / Peptides, Cyclic; 0 / Proton Pump Inhibitors; 0G3DE8943Y / lanreotide; 51110-01-1 / Somatostatin; RWM8CCW8GP / Octreotide
  • [Number-of-references] 76
  •  go-up   go-down


34. Ishida M, Niguma T, Kimura T, Mimura T, Tsutsui N: [A case report of successful control of liver metastasis from duodenal cancer with combined S-1 and docetaxel chemotherapy]. Gan To Kagaku Ryoho; 2007 Sep;34(9):1477-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of successful control of liver metastasis from duodenal cancer with combined S-1 and docetaxel chemotherapy].
  • A 70-year-old man with abdominal pain and anemia was diagnosed with duodenal cancer upon upper gastrointestinal endoscopy and biopsy.
  • Pathological findings were duodenal cancer, T 4 SI (Panc) N0P0V0A0H0.
  • He then underwent combined chemotherapy consisting of two weeks administration of S-1 (80 mg/body) followed by one week rest and injections of docetaxel (40 mg/body) every three weeks as one course.
  • Metastatic tumors were gradually reduced and successfully controlled,and there was no other recurrence until he died about three years later of another illness.
  • Combined S-1 and docetaxel chemotherapy is known to be effective for esophageal cancer, gastric cancer and other digestive cancer, as well as for duodenal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Duodenal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Drug Combinations. Humans. Male. Oxonic Acid / administration & dosage. Taxoids / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17876150.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


35. Miura T, Shimaoka Y, Nakamura J, Yamada S, Miura T, Yanagi M, Sato K, Usuda H, Emura I, Takahashi T: TTF-1 is useful for primary site determination in duodenal metastasis. World J Gastrointest Oncol; 2010 Sep 15;2(9):360-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TTF-1 is useful for primary site determination in duodenal metastasis.
  • We report here on a case of duodenal metastasis from primary lung adenocarcinoma.
  • Four courses of combined chemotherapy with carboplatin and paclitaxel associated with irradiation of 60 Gy shrunk the lung tumor.
  • Esophagogastroduodenoscopy revealed three duodenal tumors.
  • Differential diagnosis between malignant lymphoma and metastatic duodenal cancer was endoscopically difficult.
  • Thus, we concluded that these were metastatic duodenal tumors from lung adenocarcinoma.
  • Two courses of gemcitabine led to a complete remission in this duodenal metastasis and para-aortic lymph node swelling with only scarring remaining in computed tomography.
  • He is now on the continuous generalized chemotherapy.
  • In conclusion, duodenal metastasis from primary lung adenocarcinoma is rare and hard to diagnose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160807.001).
  • [ISSN] 1948-5204
  • [Journal-full-title] World journal of gastrointestinal oncology
  • [ISO-abbreviation] World J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999137
  • [Keywords] NOTNLM ; Duodenal metastasis / Lung adenocarcinoma / Thyroid transcription factor-1
  •  go-up   go-down


36. Stauffer JA, Steers JL, Bonatti H, Dougherty MK, Aranda-Michel J, Dickson RC, Harnois DM, Nguyen JH: Liver transplantation and pancreatic resection: a single-center experience and a review of the literature. Liver Transpl; 2009 Dec;15(12):1728-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications for pancreatic resection included cholangiocarcinoma (n = 6), neuroendocrine tumor (n = 5), pancreatic cancer (n = 2), gastrointestinal stromal tumor (n = 1), periampullary adenocarcinoma (n = 1), duodenal adenomas (n = 1), and benign pancreatic mass (n = 1).
  • Indications for liver transplantation were metastatic neuroendocrine tumor disease (n = 5), primary sclerosing cholangitis (n = 5), hepatitis C virus (n = 2), metastatic gastrointestinal stromal tumor (n = 1), Klatskin tumor (n = 1), alcohol cirrhosis (n = 1), alpha-1 antitrypsin deficiency (n = 1), and chemotherapy-induced cirrhosis (n = 1).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Patient Selection. Recurrence. Risk Assessment. Time Factors. Treatment Outcome. Young Adult


37. Kummar S, Ciesielski TE, Fogarasi MC: Management of small bowel adenocarcinoma. Oncology (Williston Park); 2002 Oct;16(10):1364-9; discussion 1370, 1372-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only limited information is available on the incidence, prognosis, and role of chemotherapy in the treatment of this disease.
  • We present a review of currently available clinical data to assist the practicing oncologist in the treatment of these patients.
  • Increased incidence is seen in patients with Crohn's disease, hereditary nonpolyposis colorectal cancer, and familial adenomatouspolyposis.
  • The median survival of patients with localized, locally advanced, and metastatic disease is 50.1, 22.2, and 8.6 months, respectively.
  • Few data exist on the use of (neo)adjuvant or palliative chemo(radio)therapy in this setting.
  • Fluorouracil (5-FU)based chemotherapy, as a single agent or in combination with others, has been used in most case series.
  • Duodenal adenocarcinoma accounts for more than 50% of all cases of small bowel adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Intestinal Neoplasms / drug therapy. Intestine, Small

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12435206.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


38. Aihara T, Takatsuka Y, Itoh K, Sasaki Y, Katsumata N, Watanabe T, Noguchi S, Horikoshi N, Tabei T, Sonoo H, Hiraki S, Inaji H: Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer. Oncology; 2003;64(2):124-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer.
  • OBJECTIVE: To evaluate the efficacy and toxicity of concurrent administration of doxorubicin and docetaxel, without prophylactic use of granulocyte colony-stimulating factor, as first-line chemotherapy in patients with metastatic breast cancer (MBC).
  • Treatment consisted of 50 mg/m(2) doxorubicin and 60 mg/m(2) docetaxel on day 1 every 3-4 weeks.
  • RESULTS: Patients received a total of 251 cycles of chemotherapy (median, 5 cycles; range, 1-13 cycles).
  • The median time to treatment failure was 30.1 weeks (range, 3.3-80.7 weeks).
  • There were 2 grade 4 adverse events, which included 1 bleeding duodenal ulcer and 1 hypersensitivity reaction, but grade 3 episodes were infrequent.
  • None of the patients developed congestive heart failure or asymptomatic decrease of left ventricular ejection fraction to less than 50%.
  • CONCLUSION: Concurrent administration of 50 mg/m(2) doxorubicin and 60 mg/m(2) docetaxel is active with a manageable toxicity profile as first-line chemotherapy for MBC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Injections, Intravenous. Middle Aged. Neoplasm Staging. Treatment Failure. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 12566909.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement